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ABSTRACT
Background: Esophageal adenocarcinoma (EAC) is characterized by a male 
predominance. However, variations in the sex difference across populations and 
over time have not previously been thoroughly investigated.
Results: The male-to-female ratio in EAC incidence varied greatly across 
continents, ranging from 1.03 in Africa to 7.64 in Northern America during 
2003– 2007. The ratio was high in Europe (6.04) and Oceania (6.24), and lower in 
Asia (4.37) and Latin America and the Caribbean (3.94). The sex ratio remained 
relatively stable over time in most populations. In absolute terms, the sex difference 
in EAC incidence increased over time in populations of higher incidence, while it 
remained stable or slightly decreased in low-incidence populations.
Materials and Methods: We used data from the Cancer Incidence in Five Continents 
series to compute sex-specific age-standardized rates of EAC by population. The sex 
difference in incidence was evaluated on both absolute and relative scales, measured 
by the absolute difference and ratio between sexes, respectively. 
Conclusions: This first global assessment of the sex ratio in EAC shows that the 
male predominance is particularly strong in developed countries. The underlying 
reasons remain to be identified, but the emerging EAC burden in men merits 
consideration for targeted prevention and early detection.
INTRODUCTION
Esophageal adenocarcinoma (EAC) is one of the 
two main histological types of esophageal cancer. It 
carries a poor prognosis with an overall 5-year survival 
lower than 15% [1, 2], and the incidence has been rapidly 
increasing during the past four decades in Western 
societies, particularly in white males [2, 3]. In 2012, there 
were 52,000 new patients diagnosed with EAC globally, 
and the highest incidence globally is noted in the United 
Kingdom (UK) [4].
EAC continues to fascinate researchers and others 
with its striking and enigmatic male predominance, with 
a male-to-female ratio in incidence of 4–5:1 on average 
[2–6]. The male predominance is not readily explained 
by sex differences in the exposure to the established risk 
factors for EAC, i.e., obesity, gastroesophageal reflux 
disease, Helicobacter pylori (H. pylori) infection (inverse 
association) or tobacco smoking [2, 5, 7]. Instead, it has 
been hypothesized that sex hormones and reproductive 
factors might play a role in the development of EAC or 
its precancerous lesion Barrett’s esophagus, although the 
existing evidence is far from conclusive [2, 5, 8]. 
Variations in the male predominance of EAC 
across populations and over time have, to the best of our 
knowledge, not previously been thoroughly investigated. 
A global assessment of these variations might have 
important etiological implications. Great variations in the 
sex difference in EAC incidence across populations with 
the same ethnicity or over time in the same population 
are expected to be predominantly attributable to 
environmental risk factors, while a stable sex ratio within a 
population indicates a key role of the sex itself or intrinsic 
exposures related to sex, including hormonal or genetic 
factors. Therefore, we performed a global evaluation of 




As shown in Figure 1, the male-to-female ratio in 
EAC incidence varied greatly across continents during 
the period 2003–2007, ranging from the lowest 1.03 
(95% confidence interval [CI]: 0.64, 1.64) in Africa to 
7.64 (95% CI: 7.43, 7.86) in Northern America. In other 
continents, the ratio was high in Europe (6.04, 95% CI: 
5.88, 6.20) and Oceania (6.24, 95% CI: 5.68, 6.85), but 
lower in Asia 4.37 (95% CI: 3.95, 4.84) and Latin America 
and the Caribbean 3.94 (95% CI: 3.45, 4.50). 
Countries
On a country level in 2003–2007, the lowest sex 
ratio in EAC was observed in Iran (0.98, 95% CI: 0.53, 
1.79), while the highest was found in Lithuania (9.54, 
95% CI: 5.45, 16.68). Data from countries with higher 
overall incidence rates of EAC (both sexes) provided 
more precise estimates as indicated by narrower CIs 
(Supplementary Table 1). The male-to-female ratios in 
EAC incidence in the Western countries the UK, the US, 
Canada, Australia, and the Netherlands were 4.91 (95% 
CI: 4.74, 5.09), 7.73 (95% CI: 7.51, 7.97), 6.87 (95% CI: 
6.25, 7.55), 6.25 (95% CI: 5.63, 6.93), and 5.70 (95% 
CI: 5.28, 6.15), respectively. In Asian countries, high sex 
ratios were observed in Japan (7.17, 95% CI: 5.5, 9.35) 
and the Republic of Korea (6.82, 95% CI: 5.23, 8.91), 
while these ratios were lower in other Asian countries. The 
sex ratios were higher in countries with higher incidence 
rates (Supplementary Figure 1). The ethnicity-specific 
sex ratios in the US were higher in Whites than in Asian, 
Pacific Islanders and Blacks (Table 1). In terms of absolute 
risk difference, the sex difference in EAC incidence was 
highest in the UK (5.43 per 100 000 person-years, 95% 
CI: 5.31, 5.55), followed by the Netherlands (5.32, 95% 
CI: 5.10, 5.54), Ireland (4.22, 95% CI: 3.77, 4.67), and the 
US (3.49, 95% CI: 3.44, 3.54). More detailed results for all 
countries and regions included in this study are provided 
in the Supplementary Materials (Supplementary Table 1).
Figure 1: Male-to-female ratios in age-standardized incidence rates of esophageal adenocarcinoma and their 95% 
confidence intervals by continent.
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Calendar time 
The male-to-female ratio in EAC incidence has 
remained relatively stable since the 1970 s or 1980 s in 
most populations, whereas a seemingly steady increase 
was noted in the UK (from 3.73 [95% CI: 3.36, 4.14] 
during 1978–1982 to 4.91 [95% CI: 4.74, 5.09] during 
2003– 2007) and the Netherlands (from 3.87 [95% 
CI: 3.41, 4.39] during 1988–1992  to 5.70 [95% CI: 
5.28, 6.15] during 2003–2007). The sex ratios in Canada, 
Australia, Denmark, and Japan increased from the period 
1978–1982 until the mid-to-late 1990 s, but remained 
stable or showed a slight decrease thereafter (Figure 2, 
Supplementary Table 2). In absolute terms, the sex 
difference in EAC incidence steadily increased over time 
in populations of higher incidence, but remained stable or 
slightly decreased in low-incidence populations (Figure 3, 
Supplementary Table 2).  
DISCUSSION
The present study identified a worldwide male 
predominance in EAC, which was stronger in developed 
countries. The sex ratio in EAC incidence remained 
relatively stable over time in most populations, except 
for an increase in a few countries, particularly in the UK 
and the Netherlands. The absolute difference in EAC 
incidence between the sexes steadily increased over time 
in the Western populations, indicating an emerging global 
burden of EAC in men.
The present study found that the global male 
predominance in EAC is more pronounced in Western 
populations, namely, Northern America, Europe, and 
Oceania. In Asia, the male-to-female ratios in EAC 
incidence were generally lower, although they were high 
in Japan and the Republic of Korea. These latter countries 
are more developed (“semi-Western”) countries compared 
with other Asian countries. The increasing trend of the 
male predominance from the late 1970 s to the mid-1990 s 
in Japan is in line with the post-war economic growth 
coupled with modernization in Japanese society. The 
findings of extreme male predominance in EAC in the 
developed world may be attributable to risk factors related 
to Western lifestyle. A recent analysis suggested higher 
male to female ratio in EAC incidence in populations 
with higher prevalence of obesity [9], which may partially 
explain the more pronounced male predominance in these 
more developed countries. However, the sex ratios in 
EAC incidence did not substantially change over time 
in most populations, suggesting a key role of intrinsic 
exposures (e.g., genetic factors or sex hormones), or 
some environmental exposures with stable differences in 
prevalence between the sexes. Furthermore, the sex ratios 
in EAC incidence in immigrants in the US were similar to 
those in their regions of origin, which indicates that genetic 
or ethnicity-specific lifestyle factors might be involved in 
explaining the male predominance of EAC. The slight but 
notable increased male-to-female ratio in EAC incidence 
in Canada, Japan, and possibly in the UK may, to some 
extent, be explained by more rapidly increased prevalence 
of obesity in men in these countries since the 1980s. 
However, the increased sex ratio in EAC incidence over 
time in the Netherlands, Australia, and Denmark does not 
match the relatively stable sex ratios in the prevalence of 
obesity in these countries (Supplementary Figure 2) [10]. 
Despite the generally stable sex ratios over time, the 
absolute difference between the sexes in EAC incidence 
has increased in all Western countries included in this 
study. This emerging burden of EAC in men may have 
implications for public health decision-makers in designing 
and implementing targeted prevention and measures of 
early detection of this cancer. The decreasing absolute sex 
difference in EAC incidence in Hong Kong parallels the 
decrease in prevalence of tobacco smoking in the Hong 
Kong population, which is more pronounced in women [11]. 
The male predominance in EAC is not readily 
explained by the main established risk factors for EAC, 
i.e., obesity, reflux, and H. pylori infection (inverse), since 
Table 1: Sex difference in the incidence of esophageal adenocarcinoma by ethnicity in the United 
States of America (NPCR 42 states), 2003–2007 
Ethnicities
No. of cases ASIR (95 % CI)a
RD (95% CI)a RR (95% CI)
Males Females Males Females
White 31551 5209 4.45 (4.40, 4.50) 0.57 (0.55, 0.58) 3.88 (3.83, 3.93) 7.85 (7.61, 8.10)
Asian and Pacific Islander 145 38 0.53 (0.45, 0.63) 0.11 (0.08, 0.15) 0.43 (0.33, 0.52) 5.02 (3.50, 7.19)
Black 695 249 0.94 (0.87, 1.02) 0.24 (0.21, 0.27) 0.71 (0.63, 0.78) 3.97 (3.43, 4.60)
American Indian 120 23 2.02 (1.67, 2.43) 0.35 (0.22, 0.52) 1.67 (1.28, 2.07) 5.79 (3.69, 9.08)
All 32741 5565 4.01 (3.96, 4.05) 0.52 (0.50, 0.53) 3.49 (3.44, 3.54) 7.73 (7.51, 7.97)
ASIR: age-standardized incidence rate using the World Health Organization (WHO) World Standard Population 2000 as 
the reference (1/100 000 person-years); CI: confidence interval; NPCR: National Program of Cancer Registries; RD: risk 
difference; RR: relative risk measured by the male-to-female ratio in the age-standardized incidence rate.
aIn 1/100 000 person-years.
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Figure 2: Male-to-female ratios in age-standardized incidence rates of esophageal adenocarcinoma and their 95% 
confidence intervals by calendar period in selected populations.
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Figure 3: Risk differences in age-standardized incidence rates of esophageal adenocarcinoma between the sexes (1/100 
000 person-years) and their 95% confidence intervals by calendar period in selected populations.
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the prevalences of these exposures are similar between the 
sexes and existing evidence does not support any stronger 
association between these factors and EAC in men than in 
women [2, 5, 12–14]. Abdominal obesity, as the typical 
male fat distribution and a risk factor for EAC [15], has 
been hypothesized to contribute to the male predominance 
in EAC. However, this hypothesis was not supported 
by a stratified analysis showing no increased male 
predominance among overweight EAC patients compared 
with lean [16]. Reflux disease seems to be more severe 
in men than in women [17], which may partially explain 
the male predominance in EAC as erosive reflux disease, 
which is a stronger risk factor for EAC than non-erosive 
reflux [18]. Accordingly, reflux seems to be more prevalent 
in men than in women and the prevalence of this condition 
has increased in recent decades in Japan [19, 20], which 
is in line with the increased male-to-female ratio in EAC 
incidence observed in this study. Tobacco smoking is more 
prevalent in Western women than in Asian women, which 
does not match the more distinct male predominance in 
EAC in Western countries. Moreover, there is no stronger 
association between tobacco smoking and EAC risk in 
men than in women, and the male predominance in EAC 
is similar in smokers and non-smokers [7]. Thus, the 
male predominance in EAC is unlikely to be explained 
by tobacco smoking, particularly not for the Western 
populations. Some yet unidentified risk factors associated 
with the Western lifestyle which are more prevalent 
or harmful in men may have contributed to the male 
predominance in EAC, and merit further investigation.
A 16-year delayed development of EAC in women 
compared to men has been noted, suggesting a protective 
role of endogenous estrogen in the development of 
EAC [21]. The existing evidence regarding a potential 
association between estrogen exposure and risk of EAC 
or its precancerous lesion, Barrett’s esophagus, remains 
inconclusive, however [2, 5, 8]. Based on the hypothesized 
protective role of estrogenic exposures, the increased male-
to-female ratios over time observed in several populations 
included in this study may be partially explained by 
the increasing use of oral contraceptives and hormonal 
replacement therapy [22], which may have resulted in a 
decrease of EAC risk in women in these countries. Yet, the 
role of sex hormonal factors in EAC development remains 
to be established in valid and large population-based studies. 
Another noteworthy finding of this study is that the 
incidence rates of EAC were virtually the same for both 
sexes in Iran. Interestingly, more similar incidence rates 
between the sexes than in other countries have also been 
observed for other types of male-predominant cancers, 
e.g., hepatocellular carcinoma, in Iran compared with 
other parts of world [23]. Such findings suggest distinct 
etiological profiles of gastrointestinal malignancies in the 
Iranian population, which may include some exposures 
more equally distributed between the sexes, e.g. shared 
dietary factors.
EAC carries a poor prognosis with an overall 5-year 
survival lower than 15% in Western populations, and tumor 
stage at diagnosis is by far the strongest prognostic factor 
[1, 2]. Thus, detection at an early stage would have the 
potential to greatly reduce the mortality of EAC. Upper 
endoscopy has been increasingly used for the detection 
of EAC or its precursor lesion, Barrett’s esophagus, 
particularly in patients with reflux symptoms. However, 
an unselective endoscopic surveillance, even among 
reflux patients, seems infeasible considering the low 
absolute risk of EAC in the population, the considerable 
costs, the invasiveness of the procedure, as well as its 
error prone nature, due to sampling bias and subjective 
diagnosis. Instead, targeting a limited group of individuals 
at high risk of EAC would be necessary, and the strong 
male predominance in EAC needs to be considered when 
selecting such high-risk groups. The Clinical Guidelines 
Committee of the American College of Physicians proposed 
upper endoscopy in men aged > 50 years with long-lasting 
reflux symptoms and other risk factors [24]. However, 
the benefits and risks of such a practice remain to be 
carefully weighted before it is adopted in other populations 
given the differential epidemiological features, including 
the variations in the sex difference in incidence across 
populations.
This study is the first to thoroughly investigate 
the variations in the male predominance of EAC across 
populations and over time globally. Most previous studies 
have measured the sex difference in EAC incidence in 
relative terms, which are less likely to be affected by 
changes in absolute rates and can facilitate comparisons 
between populations. However, the absolute disparity 
between the sexes could not have been reflected. In this 
study, we measured the sex difference in EAC incidence 
on both absolute and relative scales, which have provided 
fundamentally different types of information.  Moreover, 
the data from the employed cancer registers were of good 
quality [25–29]. A limitation is the risk of misclassification 
of histological typing, which may have resulted in some 
underestimation of EAC incidence in some registers, 
particularly in earlier periods. Moreover, the classification 
standards might vary between registers. However, it is 
unlikely that any misclassification or underreporting would 
have been differential between the sexes, and thus, should 
not influence the sex ratios in EAC incidence to a great 
extent. The possible histological misclassification might 
have greater impact on the estimated ratios in populations 
with high proportions of squamous cell carcinoma given 
that even a small proportion of misclassification from 
squamous cell carcinoma to adenocarcinoma might 
have led to substantial artificial changes in the estimated 
incidence rates in these populations. Such possible 
histological misclassification may be an alternative 
explanation for the lower male to female ratios in EAC 
incidence in populations with low incidence of EAC but 
higher incidence of squamous cell carcinoma.  In addition, 
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it cannot be ruled out that the absolute risk differences 
between the sexes may have been underestimated if 
inaccurate histological classification existed. 
In conclusion, this first global assessment of the 
sex ratio in EAC identified a clearly stronger male 
predominance in Western countries. The observed male 
predominance, in terms of both geographical variations 
and changes over time, might be due to a combination of 
environmental, hormonal and genetic factors, but more 
research is needed. The increasing differences in absolute 
number of cases in men compared to women indicates an 
emerging global burden of EAC in men, which needs to be 
taken into consideration when designing and implementing 
targeted prevention and measures of early tumor detection.
MATERIALS AND METHODS
Data sources
We extracted EAC incidence and population data from 
the Cancer Incidence in Five Continents (CI5) series, which 
are monographs published by the International Agency 
for Research on Cancer (IARC) containing information 
on cancer incidence from all over the world where good 
quality data are available [25, 27–29]. The volumes VII 
to X, containing detailed data with morphological coding, 
were used since it is otherwise not possible to distinguish 
EAC from the other main histological type of esophageal 
cancer, i.e., squamous cell carcinoma. We further extracted 
data from the 1970 s or early 1980 s from the CI5plus 
database, which contains updated annual incidence rates 
for selected populations up to the year 2007 [26]. Registers 
without any EAC patients in each volume were excluded. 
We pooled the numbers of cases and population sizes from 
multiple regional registers within a country if there was no 
nationwide data available. Countries with fewer than ten 
EAC patients for each sex in each volume were excluded 
due to statistical instability from including extremely low 
incidence rates, or possible incomplete histological coding.
Statistical analyses
All statistical analyses were performed using the 
statistical software SAS 9.4 (SAS Institute, Cary, NC). We 
first calculated the sex-specific crude and age-standardized 
incidence rates (ASIRs) by country and region for each 
CI5 volume in five-year calendar periods. The ASIRs were 
calculated using the direct method with the World Health 
Organization (WHO) World Standard Population 2000 as the 
reference [30]. The 95% CIs of crude rates were calculated 
under the assumption of Poisson distribution, while CIs for 
ASIRs were computed based on the gamma distribution as 
it assumes that the standardized rate is a weighted sum of 
independent Poisson random variables [31, 32]. 
Indicators of sex differences in EAC incidence were 
calculated on both absolute and relative scales, namely risk 
difference and relative risk, respectively. Risk differences 
were calculated by subtracting the ASIR in males from that 
in females, while relative risks were measured as the male-
to-female ratio in ASIR. The 95% CIs of risk differences 
and relative risks were estimated based on the assumptions 
of normal and log-normal distributions, respectively [32]. 
In the global comparisons, we present results from the 
most recent CI5 volume (number X) from 2003 to 2007, 
which contains the most complete coverage and highest 
quality of registers, including good information on EAC 
diagnosis. We further pooled the estimates for six major 
regions in the world (Africa, Latin America and the 
Caribbean, Northern America, Asia, Europe, and Oceania) 
based on the geographical definition of the United Nations’ 
World Population Prospects [33]. In addition, we estimated 
the sex difference in EAC incidence by ethnic groups in 
the United States (US). Time trends in the sex difference of 
EAC incidence were evaluated in 20 selected populations 
with available data in each of the four CI5 volumes.    
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